GemVax & KAEL

082270 · KOSDAQ · South Korea

Public Market Listing

082270KOSDAQ

KOSDAQ primary exchange listing

Live quotes, historical charts, and market capitalization for GemVax & KAEL are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Telomerase (hTERT)Peptide
Alzheimer's DiseasePancreatic Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (3)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$12M$1.6M$15M$2.0Mreport ↗
View 2 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q4$18M$1.2M$11M$1.4Mreport ↗
2025-Q3$13M$1.4M$9.1M$6.3Mreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$57M$10M$11M$12Mreport ↗

GemVax & KAEL reported revenue of $57.36M, up 24.5% YoY, R&D spend of $10.13M, down 60.7% YoY, cash and equivalents of $11.43M, and a quarterly net burn of $12.11M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$46M$26M$0.6M$62Mreport ↗
2023-FY$55M$12M$13M$16Mreport ↗